Management of Anemia in Pediatric CKD
Treat pediatric CKD anemia with weight-adjusted iron supplementation (2-3 mg/kg/day oral iron for non-dialysis patients; IV iron for hemodialysis patients) and erythropoiesis-stimulating agents (ESAs), starting with subcutaneous epoetin at 80-120 units/kg/week for older children or 300 units/kg/week for children under 5 years, targeting hemoglobin levels that improve quality of life while avoiding excessive correction.
Core Treatment Strategy
The management of anemia in pediatric CKD follows a structured approach prioritizing iron repletion and ESA therapy, with important weight-based dosing adjustments that differ from adults 1, 2.
Iron Supplementation
For Non-Dialysis and Peritoneal Dialysis Patients:
- Start with oral iron at 2-3 mg/kg/day of elemental iron in divided doses 1
- Use ionic iron salts (sulfate, fumarate, or gluconate) as they provide known amounts of elemental iron at lower cost 1
- Administer away from meals (food reduces absorption by 50%) and avoid concurrent aluminum-based phosphate binders 1
- Monitor response at 3-month intervals; approximately 30% of children will not respond adequately to oral iron 3
For Hemodialysis Patients:
IV iron is preferred due to substantial ongoing blood losses and superior efficacy 1. Weight-based dosing is critical:
10-Dose Course for Hemodialysis:
- Children <10 kg: 25 mg per dose
- Children 10-20 kg: 50 mg per dose
- Children >20 kg: 100 mg per dose 1
For Pre-Dialysis/PD Patients (single infusion):
- Children <10 kg: 125 mg
- Children 10-20 kg: 250 mg
- Children >20 kg: 500 mg 1
Critical caveat: There are no studies on maintenance IV iron dosing in pediatric patients, representing a significant knowledge gap 1. Adult maintenance regimens (250-1,000 mg over 12 weeks) may need pediatric adaptation but lack evidence 1.
Iron Status Monitoring
- Measure transferrin saturation (TSAT) and serum ferritin every 3 months during maintenance 1
- Target TSAT >20% and ferritin >100 ng/mL for non-dialysis patients, >200 ng/mL for hemodialysis patients 1, 4
- Important limitation: These parameters are not reliable for estimating body iron stores or predicting treatment response in CKD 4
- Wait 2-7 days after IV iron doses of 100-125 mg before measuring iron parameters; wait 14 days after doses ≥1 gram 1
Erythropoiesis-Stimulating Agent Therapy
Subcutaneous administration is strongly preferred over IV due to superior pharmacodynamics and 15-50% lower dose requirements 1.
Initial Dosing:
- Children >5 years and adults: 80-120 units/kg/week SC, divided into 2-3 doses per week 1
- Children <5 years: Require substantially higher doses of 300 units/kg/week due to unclear physiologic differences 1
- For hemodialysis patients receiving IV epoetin: 120-180 units/kg/week in 3 divided doses 1
Dose Titration:
- Target slow, steady hemoglobin increase over 2-4 months (matching RBC lifespan) 1
- Monitor hemoglobin every 2-4 weeks initially, then monthly once stable
- Adjust dose by 25% increments based on response 1
Route Conversion:
- When switching from IV to SC in patients at target hemoglobin: reduce weekly dose by 33% 1
- When switching before reaching target: maintain same total weekly dose but divide into 2-3 SC doses 1
Pathophysiology Considerations
Anemia in pediatric CKD results from multiple mechanisms 1, 5, 6:
- Primary cause: Insufficient erythropoietin production by diseased kidneys
- Iron deficiency: Both absolute (depleted stores) and functional (hepcidin-mediated restriction of iron release despite adequate stores)
- Contributing factors: Shortened RBC survival, inflammation, hyperparathyroidism, blood losses from phlebotomy and dialysis
In hemodialysis patients specifically, cumulative annual iron losses approximate 1.6 g/1.73 m² BSA from GI bleeding (11 mL/m²/day) and dialysis-associated losses (8 mL/m²/treatment) 1.
Treatment Response and Monitoring
Expected Outcomes with Oral Iron:
- Hemoglobin improvement of approximately 0.4-0.6 g/dL over 3 months 3
- Anemia resolution (by KDIGO criteria) in only 29% of children 3
- 35% show no hemoglobin improvement and 27% show no TSAT improvement 3
- Children with more severe baseline anemia respond better to oral iron 3
When to Escalate to IV Iron:
- Failure to respond to 3 months of oral iron therapy
- Hemodialysis patients (first-line therapy)
- Intolerance to oral iron (GI side effects)
- Need for rapid iron repletion 1
Critical Pitfalls to Avoid
Underdosing young children: Children <5 years require 2.5-3.75 times higher ESA doses per kilogram than older children and adults 1
Premature iron supplementation: Recent evidence suggests postponing iron therapy for 12 weeks in children with mild anemia and KDIGO-defined iron deficiency does not compromise physical activity, muscle function, or quality of life 7
Over-reliance on ferritin/TSAT: These markers have significant limitations in CKD and may not accurately predict treatment response 4
Rapid hemoglobin correction: Target gradual increases over 2-4 months to avoid cardiovascular complications seen with aggressive correction in adults 1
Ignoring oral iron absorption barriers: Food, phosphate binders, and elevated ferritin (>100 ng/mL) all impair absorption 1
Novel Considerations
While hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) represent emerging therapy, they are not recommended for pediatric patients pending dedicated safety and efficacy studies 4. ESAs remain the first-line erythropoietic therapy 8.
The 2026 KDIGO guidelines emphasize proactive IV iron use in hemodialysis patients and preference for ESAs over HIF-PHIs due to greater safety familiarity 8, 9. However, pediatric-specific evidence remains limited, with most recommendations extrapolated from adult data 2.
Quality of Life Impact
Untreated anemia in pediatric CKD causes decreased tissue oxygen delivery, cardiac enlargement, growth retardation, decreased intellectual performance, and impaired immune function 1. Treatment improves these outcomes and reduces morbidity and mortality 1, 5.